Antibody-Drug Conjugate (ADC)

Service Pages

Questions?

Home 5 Service 5 Antibody-Drug Conjugate (ADC)

ChemPartner has a top-tier antibody drug conjugate (ADC) team spanning multiple areas, such as antibody development, medicinal chemistry, DMPK, and in vitro/in vivo pharmacology. In addition to individual function service packages, ChemPartner also provides all-in-one ADC development service packages from antibody generation to IND filing.

Our scientists are highly skilled in the design and synthesis of a variety of toxins and linkers, such as the mechanistically diverse MMAE/MMAF, Maytansine derivatives, Duocarmycin, Nemorubicin, and pyrrolobenzodiazepines. We purify and characterize ADCs using state-of-the-art technologies. A dedicated, certified, high-potency lab is fully operational and capable of handling Active Pharmaceuticals Ingredients (APIs) with Occupational Exposure Limit (OEL) < 1 μg/m3 at scale up to 50 grams.

Our biologics team is able to develop antibodies from scratch using single B cell cloning, phage display, or hybridoma approaches. Our manufacturing (CMC) team has GMP compliant antibody production and fill-finish capacity of up to 400 grams. 

The ADC team has early discovery, optimization, and evaluation capacity using different antibody, linker, and toxin combinations. The GLP CMC facility has the production capacity for producing up to 40 grams.

All ADC-related functions and developments are fully supported with a well-equipped, state-of-the-art analytical facility. The ADC team has worked with many pharmaceutical and biotech companies on novel toxins to create novel ADCs with additional mechanisms of action.

Flexible Early Clinical Development

  • Antibody development from antigen generation to cell line development
  • Customized toxin/linker design and synthesis
  • Preparation of ADC sample panels using a variety of linker/toxin/mAb combinations
  • ADC scale-up process development and formulation development
  • Dedicated ADC R&D teams ready for new projects and drop-ins
  • GLP ADC production up to 40 grams
  • DMPK and in vivo pharmacology team support IND-enabling studies

ADC Analytical Services

  • Complete analytical development packages with mAb/ADC harmonization
  • Comprehensive ADC specific bioassay
  • ADC release and stability testing
  • Pharmacology, PK/PD & Exploratory Toxicology
  • Dedicated ADC QC teams to support new method development or method transfers

Case Study on T-DM1 (Kadcyla)

Headquarters

1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203

w

Contact Us

China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000
Japan: +81 03 5403 6975

contact@chempartner.com